CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-24). The draft was written by AI, the existence of all 2 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 1644 · Search date 2026-07-24 · Methodology v0.6

Magnesium chloride,
does it really help with Improved fasting and post-load glucose in adults with both prediabetes and hypomagnesemia?

30-Second Summary
C
Evidence Grade C · 44 · Safety caution
Glucose values improved in prediabetes with hypomagnesemia, but prevention of diabetes remains unproven
What the
research shows
Oral magnesium chloride is rated C because a small randomized trial improved fasting and post-load glucose over four months in adults who had both prediabetes and hypomagnesemia. The peer-reviewed double-blind original included 116 participants in the actual primary analysis, and its primary endpoint of lowering plasma glucose succeeded. Fasting glucose was 86.9 versus 98.3 mg/dL and two-hour post-load glucose was 124.7 versus 136.7 mg/dL. Glucose is nevertheless a surrogate for diabetic complications or clinical events, and the trial did not test prevention of diabetes or complications. Rule ①-ⓐ therefore caps the grade at C.
What the
ads claim
Marketing can expand the finding into a claim that magnesium normalizes glucose and prevents diabetes. The direct evidence only shows better laboratory values after 116 adults with confirmed prediabetes and hypomagnesemia used a 5% magnesium chloride solution for four months; prevention of diabetes and complications remains unproven.
*

Useful facts when choosing a product

  • The trial dose was 30 mL of a 5% magnesium chloride solution once daily, providing 382 mg of elemental magnesium.
  • Direct evidence applies to adults with laboratory-confirmed hypomagnesemia as well as prediabetes, not to all people with prediabetes.
  • Supplemental magnesium can cause diarrhea, abdominal pain, and nausea, while impaired kidney function raises the risk of hypermagnesemia.
  • Magnesium can impair absorption of some antibiotics, bisphosphonates, and thyroid hormone, so dose separation should be checked with a clinician or pharmacist.
Gap Measurement · Verdict 1644 · C 44
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

The publication form was a peer-reviewed original double-blind placebo-controlled randomized trial in Diabetes & Metabolism. The actual primary analysis included 116 participants, and the primary endpoint of plasma-glucose reduction succeeded. After four months, fasting glucose was 86.9±7.9 with magnesium chloride versus 98.3±4.6 mg/dL with placebo (P=0.004), while two-hour post-load glucose was 124.7±33.4 versus 136.7±23.9 mg/dL (P=0.03). A 2021 meta-analysis of double-blind trials pooled improved fasting glucose across 11 high-risk trials and two-hour glucose across three trials, but fasting-glucose heterogeneity was I² 81.2% and the evidence did not establish incident diabetes, microvascular outcomes, or cardiovascular outcomes.

02

Why this is classified as C (44)

A single four-month randomized trial in 116 people with prediabetes and hypomagnesemia succeeded on a plasma-glucose endpoint, but fasting and two-hour glucose are laboratory surrogates and no incident-diabetes, complication, or other clinical outcome was measured. The evidence is limited to concomitant hypomagnesemia, giving a low C with 44 points.

Counterpoint. Weight management, diet, activity, sleep, and validated prevention programs remain foundational in prediabetes. Magnesium should be an adjunct considered after assessing deficiency, kidney function, and medicine interactions.

Rejudgment record. Cross-check applied — C recognizes success of the primary plasma-glucose endpoint in 116 actual participants in the peer-reviewed double-blind original, while applying the rule ①-ⓐ ceiling because fasting and post-load glucose are surrogates and no incident-diabetes or complication hard outcome exists

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Improved fasting glucose in prediabetes with hypomagnesemiaCThe 116-person trial and high-risk meta-analysis were positive, but the outcome is a laboratory surrogate and heterogeneity is substantial.
Improved two-hour post-load glucose in prediabetes with hypomagnesemiaCThe direct randomized trial was significant, but this is a small, short-term surrogate endpoint.
Prevention of incident type 2 diabetes with oral magnesium chloride?No human efficacy trial was found that primarily tested incident diabetes with this formulation in this population.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Guerrero-Romero F et al. 2015Peer-reviewed original randomized double-blind placebo-controlled trial116Academic research; commercial sponsorship was not clearly reported in the originalPrimary endpoint of reduced plasma glucoseThe primary endpoint succeeded; fasting glucose was 86.9 versus 98.3 mg/dL (P=0.004), and two-hour glucose was 124.7 versus 136.7 mg/dL (P=0.03).Direct small surrogate-endpoint randomized trial
Veronese N et al. 2021Systematic review and meta-analysis of double-blind randomized trials210Reported no external fundingFasting glucose, two-hour oral-glucose-tolerance glucose, HOMA-IR, and HbA1cFasting and two-hour glucose improved in high-risk groups, but fasting-glucose heterogeneity was I² 81.2%, HbA1c was not significant, and hard outcomes were absent.Supportive surrogate synthesis with heterogeneity
§

Receipt — 2 References

All 2 cited sources were verified for existence at the original page (as of 2026-07-24).

Guerrero-Romero F, Simental-Mendía LE, Hernández-Ronquillo G, Rodríguez-Morán M. Oral magnesium supplementation improves glycaemic status in subjects with prediabetes and hypomagnesaemia: a double-blind placebo-controlled randomized trial. Diabetes Metab. 2015;41(3):202-207. PMID: 25937055. DOI: 10.1016/j.diabet.2015.03.010.
checked
Veronese N, Dominguez LJ, Pizzol D, Demurtas J, Smith L, Barbagallo M. Oral Magnesium Supplementation for Treating Glucose Metabolism Parameters in People with or at Risk of Diabetes: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials. Nutrients. 2021;13(11):4074. PMID: 34836329. PMCID: PMC8619199. DOI: 10.3390/nu13114074.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-24 · Corrections: none

Cite this verdict

Magnesium chloride x improved fasting and post-load glucose in prediabetes with hypomagnesemia Evidence Grade C card
[Chamgap] Magnesium chloride x improved fasting and post-load glucose in prediabetes with hypomagnesemia — Evidence Grade C·44. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/blood-sugar/oral-magnesium-chloride-prediabetes-hypomagnesemia-glucose/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.